Niaz Osamah S, Rao Ahsan, Abidia Ahmed, Parrott Rebecca, Refson Jonathan, Somaiya Pranav
Department of Vascular Surgery, The Princess Alexandra Hospital, Harlow, UK.
Harlow Healthcare Library, The Princess Alexandra Hospital, Harlow, UK.
Cochrane Database Syst Rev. 2020 Aug 5;8(8):CD013469. doi: 10.1002/14651858.CD013469.pub2.
Abdominal aortic graft infections are a major complication following abdominal aortic aneurysm surgery, with high morbidity and mortality rates. They can be treated surgically or conservatively using medical management. The two most common surgical techniques are in situ replacement of the graft and extra-anatomical bypass. Medical management most commonly consists of a course of long-term antibiotics. There is currently no consensus on which intervention (extra-anatomical bypass, in situ replacement, or medical) is the most effective in managing abdominal aortic graft infections. Whilst in emergency or complex situations such as graft rupture surgical management is the only option, in non-emergency situations it is often personal preference that influences the clinician's decision-making.
To assess and compare the effects of surgical and medical interventions for abdominal aortic graft infections.
The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL databases and WHO ICTRP and ClinicalTrials.gov trials registers to 2 December 2019. We also reviewed the bibliographies of the studies identified by the search and contacted specialists in the field and study authors to request information on any possible unpublished data.
We aimed to include all randomised controlled trials that used surgical or medical interventions to treat abdominal aortic graft infections. The definitions of abdominal aortic graft infections were accepted as presented in the individual studies, and included secondary infection due to aortoenteric fistula. We excluded studies presenting data on prosthetic graft infections in general, unless data specific to abdominal aortic graft infections could be isolated.
Two review authors independently assessed all studies identified by the search. We planned to independently assess risk of bias of the included trials and to evaluate the quality of the evidence using the GRADE approach. Our main outcomes were overall mortality, amputation, graft re-infection, overall graft-related complications, graft-related mortality, acute limb ischaemia, and re-intervention.
We identified no randomised controlled trials to conduct meta-analysis.
AUTHORS' CONCLUSIONS: There is currently insufficient evidence to draw conclusions to support any treatment over the other. Multicentre clinical trials are required to compare different treatments for the condition.
腹主动脉移植物感染是腹主动脉瘤手术后的一种主要并发症,发病率和死亡率都很高。可通过手术治疗或采用药物治疗进行保守治疗。两种最常见的手术技术是原位更换移植物和解剖外旁路手术。药物治疗通常包括一个长期抗生素疗程。目前对于哪种干预措施(解剖外旁路手术、原位更换或药物治疗)在治疗腹主动脉移植物感染方面最有效尚无共识。虽然在紧急情况或复杂情况(如移植物破裂)下,手术治疗是唯一选择,但在非紧急情况下,往往是个人偏好影响临床医生的决策。
评估和比较手术和药物干预对腹主动脉移植物感染的效果。
Cochrane血管信息专家检索了Cochrane血管专业注册库、CENTRAL、MEDLINE、Embase和CINAHL数据库以及世界卫生组织国际临床试验注册平台(WHO ICTRP)和ClinicalTrials.gov试验注册库,检索截至2019年12月2日的数据。我们还查阅了检索到的研究的参考文献,并联系了该领域的专家和研究作者,以获取任何可能未发表数据的信息。
我们旨在纳入所有使用手术或药物干预治疗腹主动脉移植物感染的随机对照试验。腹主动脉移植物感染的定义按照各研究中的定义采用,包括由于主动脉肠瘘引起的继发性感染。我们排除了一般情况下关于人工血管移植物感染的数据的研究,除非能够分离出腹主动脉移植物感染的特定数据。
两位综述作者独立评估了检索到的所有研究。我们计划独立评估纳入试验的偏倚风险,并使用GRADE方法评估证据质量。我们的主要结局指标包括总死亡率、截肢、移植物再感染、与移植物相关的总体并发症、与移植物相关的死亡率、急性肢体缺血和再次干预。
我们未找到可进行荟萃分析的随机对照试验。
目前没有足够的证据得出支持一种治疗优于另一种治疗的结论。需要进行多中心临床试验来比较针对该病症的不同治疗方法。